Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer

ESMO 2026: Highlights and analysis

Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer

AI-based digital MammaPrint assay predicts recurrence risk and survival in early-stage breast cancer

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer

Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results

Safeguarding the right to work for people with advanced breast cancer (ABC) and their caregivers: A global snapshot of legislati

Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Defining breast cancer quality care around the globe

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer